3. Intangible Assets, Goodwill and Other

3 Months Ended

Mar. 31, 2022

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Goodwill by segment are as follows (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2021:
Goodwill	$	333.3	$	349.2	$	682.5
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	291.5		55.8		347.3


Adjustments	(1.6)		—		(1.6)




Balances as of March 31, 2022:
Goodwill	$	331.7	$	349.2	$	680.9
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	$	289.9	$	55.8	$	345.7

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):


	March 31, 2022
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.18	$	110.6	$	(91.2)	$	19.4
Know how	3.50	169.1		(153.5)		15.6
Developed product technology	13.28	214.1		(116.8)		97.3
Licenses	6.56	59.2		(35.9)		23.3
Tradenames	7.18	6.3		(4.4)		1.9
Covenants not to compete	3.60	6.4		(3.1)		3.3


Total finite-lived intangible assets		565.7		(404.9)		160.8
In-process research and development		86.3		—		86.3
Total purchased intangible assets		$	652.0	$	(404.9)	$	247.1


	December 31, 2021
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.27	$	111.8	$	(90.7)	$	21.1
Know how	3.75	171.6		(154.9)		16.7
Developed product technology	13.42	215.6		(115.6)		100.0
Licenses	6.79	64.9		(40.6)		24.3
Tradenames	7.33	6.3		(4.4)		1.9
Covenants not to compete	3.78	6.5		(2.9)		3.6


Total finite-lived intangible assets		576.7		(409.1)		167.6
In-process research and development		86.3		—		86.3
Total purchased intangible assets		$	663.0	$	(409.1)	$	253.9

Amortization expense related to purchased intangible assets is as follows (in millions):